Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol

Experimental Eye Research

Volumn 100, Issue , 2012, Pages 59-64

  Qiao, Zhuanhong ^a   Kumar, Akhilesh ^a   Kumar, Pritesh ^a   Song, Zhao Hui ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Abn cbd; Abnormal cannabidiol; Aqueous humor outflow; Cannabinoid receptor; GPCR; Intraocular pressure; IOP; P42 44 MAPK; P42 44 mitogen activated protein kinase; TM; Trabecular meshwork

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ABNORMAL CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P42/44; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR OUTFLOW; ARTICLE; CELL CULTURE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; WESTERN BLOTTING;

ANIMALS; ANISOLES; AQUEOUS HUMOR; BLOTTING, WESTERN; CANNABINOIDS; CELLS, CULTURED; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ORGAN CULTURE TECHNIQUES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RESORCINOLS; SWINE; TRABECULAR MESHWORK;

EID: 84862660263     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2012.05.001     Document Type: Article

References (33)

1. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J. Biol. Chem. 1995, 270:27489-27494.
2. Alexander J.P., Acott T.S. Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest. Ophthalmol. Vis. Sci. 2003, 44:164-169.
3. Bradley J.M., Vranka J., Colvis C.M., Conger D.M., Alexander J.P., Fisk A.S., Samples J.R., Acott T.S. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 1998, 39:2649-2658.
4. Colasanti B.K. Ocular hypotensive effect of marihuana cannabinoids: correlate of central action or separate phenomenon?. J. Ocul. Pharmacol. 1986, 2:295-304.
5. Crowston J.G., Weinreb R.N. Glaucoma medication and aqueous humor dynamics. Curr. Opin. Ophthalmol. 2005, 16:94-100.
6. Cunningham A.J., Barry P. Intraocular pressure-physiology and implications for anaesthetic management. Can. Anaesth. Soc. J. 1986, 33:195-208.
7. Gatley S.J., Gifford A.N., Volkow N.D., Lan R., Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 1996, 307:331-338.
8. Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch. Ophthalmol. 1998, 116:1433-1437.
9. He F., Song Z.H. Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol. Vis. 2007, 13:1348-1356.
10. Hepler R.S., Frank I.R. Marihuana smoking and intraocular pressure. JAMA: J. Am. Med. Assoc. 1971, 217:1392.
11. Howlett A.C. Cannabinoid Receptor Signaling. Handbook of Experimental Pharmacology 2005, 53-79 pp.
12. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U S A 1999, 96:14136-14141.
13. Jarvinen T., Pate D.W., Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol. Ther. 2002, 95:203-220.
14. Johnson D.H., Tschumper R.C. Human trabecular meshwork organ culture. A new method. Invest. Ophthalmol. Vis. Sci. 1987, 28:945-953.
15. Mo F.M., Offertaler L., Kunos G. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur. J. Pharmacol. 2004, 489:21-27.
16. Njie Y.F., He F., Qiao Z., Song Z.H. Aqueous humor outflow effects of 2-arachidonylglycerol. Exp. Eye Res. 2008, 87:106-114.
17. Njie Y.F., Kumar A., Qiao Z., Zhong L., Song Z.H. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest. Ophthalmol. Vis. Sci. 2006, 47:1999-2005.
18. Njie Y.F., Qiao Z., Xiao Z., Wang W., Song Z.H. N-arachidonylethanolamide-induced increase in aqueous humor outflow facility. Invest. Ophthalmol. Vis. Sci. 2008, 49:4528-4534.
19. Offertaler L., Mo F.M., Batkai S., Liu J., Begg M., Razdan R.K., Martin B.R., Bukoski R.D., Kunos G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. 2003, 63:699-705.
20. Pang I.H., McCartney M.D., Steely H.T., Clark A.F. Human ocular perfusion organ culture: a versatile ex vivo model for glaucoma research. J. Glaucoma 2000, 9:468-479.
21. Pertwee R.G. Pharmacological Actions of Cannabinoids. Handbook of Experimental Pharmacology 2005, 1-51 pp.
22. Polansky J.R., Weinreb R.N., Baxter J.D., Alvarado J. Human trabecular cells. I. Establishment in tissue culture and growth characteristics. Invest. Ophthalmol. Vis. Sci. 1979, 18:1043-1049.
23. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350:240-244.
24. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 1998, 284:644-650.
25. Shearer T.W., Crosson C.E. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 2002, 43:3016-3020.
26. Stamer W.D., Golightly S.F., Hosohata Y., Ryan E.P., Porter A.C., Varga E., Noecker R.J., Felder C.C., Yamamura H.I. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur. J. Pharmacol. 2001, 431:277-286.
27. Straiker A., Stella N., Piomelli D., Mackie K., Karten H.J., Maguire G. Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc. Natl. Acad. Sci. U S A 1999, 96:14565-14570.
28. Szczesniak A.M., Maor Y., Robertson H., Hung O., Kelly M.E. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. J. Ocul. Pharmacol. Ther. 2011, 27:427-435.
29. Tomida I., Pertwee R.G., Azuara-Blanco A. Cannabinoids and glaucoma. Br. J. Ophthalmol. 2004, 88:708-713.
30. Toris C.B. Pharmacotherapies for glaucoma. Curr. Mol. Med. 2010, 10:824-840.
31. Tripathi R.C., Tripathi B.J. Human trabecular endothelium, corneal endothelium, keratocytes, and scleral fibroblasts in primary cell culture. A comparative study of growth characteristics, morphology, and phagocytic activity by light and scanning electron microscopy. Exp. Eye Res. 1982, 35:611-624.
32. Weinreb R.N., Khaw P.T. Primary open-angle glaucoma. Lancet 2004, 363:1711-1720.
33. Zhong L., Geng L., Njie Y., Feng W., Song Z.H. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest. Ophthalmol. Vis. Sci. 2005, 46:1988-1992.